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Abstract
Isolated trisomy 8 is not considered presumptive evidence of myelodysplastic syndrome
(MDS) in cases without minimal morphological criteria. One reason given is that trisomy 8
(+8) can be found as a constitutional mosaicism (cT8M). We tried to clarify the incidence of
cT8M in myeloid neoplasms, specifically in MDS, and the diagnostic value of isolated +8 in
MDS. Twenty-two MDS and 10 other myeloid neoplasms carrying +8 were studied. Trisomy
8 was determined in peripheral blood by conventional cytogenetics (CC) and on granulo-
cytes, CD3+ lymphocytes and oral mucosa cells by fluorescence in situ hybridization
(FISH). In peripheral blood CC, +8 was seen in 4/32 patients. By FISH, only one patient with
chronic myelomonocytic leukemia showed +8 in all cell samples and was interpreted as a
cT8M. In our series +8 was acquired in all MDS. Probably, once discarded cT8M by FISH
from CD3+ lymphocytes and non-hematological cells, +8 should be considered with enough
evidence to MDS.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of acquired clonal hematopoiet-
ic stem cell disorders with increased risk of acute myeloid leukemia (AML) development. Diag-
nosis of MDS remains among the most challenging of the myeloid neoplasms and is based on
the presence of cytopenia(s), dysplasia in one or more myeloid lineages and less than 20% bone
marrow (BM) or peripheral blood (PB) blasts [1,2]. Around 50% of MDS cases presented clon-
al cytogenetic abnormalities [2]. Trisomy 8 (+8) is the most common chromosome gain in
MDS and is present in 5–7% of them [3]. MDS patients with isolated +8 are included in the
MDS intermediate cytogenetic risk group according to the new revised IPSS (IPSS-R) [4]. Nev-
ertheless, in contrast to other recurring chromosomal alterations, the presence of +8 as the sole
cytogenetic abnormality is not considered definitive evidence for MDS in the absence of mor-
phological criteria [2]. Since trisomy 8 was found as a constitutional mosaicism (cT8M) in
healthy people, it was not considered a tumour marker by some authors [5]. However, the inci-
dence of cT8M referred is very low; Nielsen andWohlert detected one case of cT8M among ap-
proximately 35000 live births [6], and Seghezzi et al. found two cases out of 40140 [7]. In
addition, some studies suggested that +8 could be present as a cT8M in myeloid malignancies
[7–10], and Maserati et al. reported that +8 is constitutional in 15–20% of MDS and acute leu-
kemia [9]. We have analyzed the presence of +8 in granulocytes and CD3+ lymphocytes from
PB, as well as in oral mucosa cells from patients diagnosed with MDS carrying +8, in order to
clarify the incidence of cT8M in MDS and try to provide a precise diagnostic and prognostic
value for isolated +8, especially in cases where there is a degree of doubt.
Methods
A total of 32 patients with +8 were studied from different Spanish hospitals belonging to the
Grupo español de síndromes mielodisplásicos (GESMD): 22 diagnosed with MDS and 10 of
other myeloid neoplasms. The latter group included four patients with myelodysplastic/ myelo-
proliferative neoplasm [two chronic myelomonocitic leukemia (CMML) and two refractory
anemia with ring sideroblasts and thrombocytosis (RARS-T)] and six patients with AML. Five
of the MDS and two of the AML patients had additional cytogenetic alterations to +8 on the
bone marrow karyotype. One of the AML had a tetrasomy 8. Furthermore, we also studied 20
healthy controls (12 women and 8 men), with ages ranged between 20–60 years.
Blood Samples
Lymphocytes and granulocytes were isolated from 30mL of PB using standard cell separation
protocols. CD3+ cells were isolated from mononuclear cells by immunomagnetic beads (Milte-
nyiBiotec, Germany). Afterwards, CD3+ cells, as well as granulocytes, were fixed with Carnoy
fixative solution (3:1 methanol to acetic acid), and spread on independent slides for fluores-
cence in situ hybridization (FISH) studies. The decision to study CD3+ cells was based on the
discarted involvement of them in MDS [11–16], their practical accessibility, and the recom-
mendations of other authors for germline analisis in SNP and sequencing studies [17–19].
Oral Mucosa
The oral mucosa was scraped with a sterile cotton swab. Four smears were made by scattering
mucosa cells of the swabs over slides. The samples were fixed 10 min in Carnoy solution. Once
dried, slides were treated with acetic acid solution (3:2 acetic acid to methanol) at 45°C for
40 min, following with a 10 min digestion in 0.005% pepsin solution (Sigma Aldrich, St Louis,
MO) at 37°C, and ending with a dehydratation in 70%, 80% and 100% ethanol wash series.
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Karyotype Analysis
Metaphase staining chromosome analysis using phytohemagglutinin (PHA) stimulated cul-
tures of PB were carried out by G-banding technique. At least 15 metaphases were analyzed for
each patient. The analysis and nomenclature of the chromosomes were based on International
System for Human Cytogenetic Nomenclature (ISCN) of 2013 [20].
Fluorescence in situ Hybridization (FISH)
The centromeric 8 spectrum-orange DNA probe (CEP 8, Vysis, Downers Grove, IL) was ap-
plied to CD3+ lymphocytes, granulocytes and oral mucosa cells slides. The hybridization was
performed overnight at 37°C. After washing, slides were counterstained with diaminophenylin-
dole (DAPI II). The results of the hybridization were evaluated in a fluorescence microscope. If
three signals of the same size and intensity were separated by at least one domain, +8 was con-
sidered. Following the European Cytogeneticists Association Specific Constitutional Guidelines
[21], +8 mosaicism was assessed in 200 nuclei for CD3+ lymphocytes and granulocytes, and a
minimum of 30 mucosa cells were analyzed. According to our laboratory, cutoff points for PB
samples as well as for oral mucosa cells were 5%.
The study was carried out in accordance with the biomedical Helsinki Declaration of re-
search guidelines and was approved by the Comité Ético de Investigación Clínica (CEIC) Parc
de Salut Mar. All participants provided their written informed consent to participate in
the study.
Statistical analysis
Overall survival (OS) and time to AML transformation of patients with MDS and +8 were cal-
culated. They were defined to be the time from the MDS diagnosis to death or last follow-up
and to development of AML, respectively. Kaplan-Meier method was used to evaluate OS and
AML transformation. Data analysis was performed using the R software package (version
3.1.1; R Foundation for Statistical Computing, Vienna, Austria).
Results
The patient characteristics are shown in Table 1. Among 22 patients diagnosed with MDS and
+8, 17 cases had isolated +8 on BM karyotype at diagnosis, and five had also other additional
alterations. Cytogenetic analysis of PB PHA-stimulated cultures revealed +8 in 3 out of 22 pa-
tients in 5% to 65% of cells. Using FISH, trisomy 8 was observed in 3% to 74% of granulocytes
from all 18 patients studied (4 patients were not studied for extremely neutropenia). Two of
them were not considered positive for not reaching our cut off. For CD3+ cells samples, triso-
my 8 was seen in 5 out of 22 patients. However, only 4 of them showed trisomy 8 over 5% (6%
to 20%). Probably, those cells with +8 detected in CD3+ isolated samples were monocytes due
to contamination during cellular isolation (CD3+ cell purity being 76 to 91.1%). None of the
oral mucosa cell slides from 20 patients that could be analyzed showed +8, the other two cases
could not be analyzed for unsuccessful hybridization.
Among the ten patients with other myeloid neoplasms carrying +8, neither patients with
RARS-T nor AML ones presented +8 on CD3+ lymphocytes and oral mucosa cells, while one
of CMML patients showed trisomy 8 on both of them (CD3+ lymphocytes and oral mucosa
cells).
For the healthy controls, the median of CD3+ cells with trisomy 8 was 1.3% and no cell
from mucosa samples showed trisomy 8.
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Table 1. Patient Characteristics.
FLUORESCENCE IN SITU HYBRIDIZATION
CD3
+ LYMPHOCYTES
GRANULOCYTES MUCOSA
WHO BONE MARROW KARYOTYPE PB KARYOTYPE
(PHA)
% cells
with +8
% of
purity
% cells with +8 % cells
with +8
N° of cells
analyzed
MDS
1 RA 46,XX,del(5)(q13q33)[10]/47,sl,+8[3]/48,
sld1,+22[4]/47,XX,+8[5]/46,XX[4]
46,XX[20] 0 96 20 0 46
2 RA 47,XY,+8[4]/46,XY[12] 46,XY[15] 0 96 3 0 100
3 RCUD 47,XX,+8[11]/46,XX[9] 46,XX[20] 0 88 74 0 75
4 RCMD 47,XX,+8[10]/46,XX[10] 47,XX,+8[5]/46,XX
[15]
6 91.1 - 0 100
5 RCMD 47,XY,del(5)(q15q33),+8[20] 46,XY[15] 0 95 - 0 100
6 RCMD 47,XY,+8[10]/46,XY[10] 46,XY[15] 7 86 69 0 100
7 RCMD 47,XY,+8[7]/46,XY[13] 46,XY[15] 0 85 - 0 100
8 RCMD 47,XY,+8[15]/46,XY[5] 48,XY,+8,+21[1]/46,
XY[19]
20 86 63 0 100
9 RCMD 47,XY,+8[16]/46,XY[4] 46,XY[20] 0 90 30 0 73
10 RCMD 47,XX,+8[20]/48,sl,+8[1]/46,XX[7] 46,XX[15] 0 92 31 - -
11 RCMD 47,XX,+8[5]/46,XX[15] 46,XX[20] 0 89 - 0 41
12 RCMD 47,XY,+8[8]/46,XY[12] 46,XY[20] 0 80 13 0 50
13 RCMD 47,XX,+8[5]/46,XX[26] 46,XX[15] 0 82 3 0 100
14 RCMD 47,XY,+8[13]/46,XY[7] 46,XY[20] 0 78 17 0 70
15 RCMD 47,XX,+8[20] 46,XX[20] 2 92 60 - -
16 RCMD 46,XX,del(5)(q14)[15]/47,XX,+8[2] 46,XX[15] 0 87 5 0 30
17 RCMD 47,XY,+8[8]/46,XY[15] 46,XY[20] 0 93 24 0 100
18 RAEB-1 47,XX,+8[9]/47,sl,i(17)(q10)[9] No metaphases 0 90 73 0 76
19 RAEB-2 47,XY,+8[7]/46,XY[13] 46,XY[20] 0 93 43 0 53
20 RAEB-2 47,XX,+8[2]/46,XX[18] 46,XX[20] 0 89 6 0 72
21 RAEB-2 45,X,-Y[8]/46,X,-Y,+8[5] 46,X,-Y,+8[13]/46,
XY[7]
0 96.7 47 0 54
22 MDS-U 47,XY,+8[19]/46,XY[1] 46,XY[20] 10 76 67 0 65
MDS/MPN
23 RARS-T 47,XX,+8[4]/46,XX[23] 46,XX[15] 0 93 - 0 31
24 RARS-T 47,XY,+8[3]/46,XY[17] 46,XY[15] 0 87 8 0 36
25 CMML 47,XY,+8[20] 46,XY[15] 8 84.7 - 0 80
26 CMML 47,XY,+8[15]/46,XY[5] 47,XY,+8[2]/46,XY
[48]
28 93 - 60 100
AML
27 AML-MDRC 47,XY,+8[2]/46,XY[2] 46,XY[15] 0 92 7 0 41
28 AML NOS No metaphases (FISH+8, 70%) 46,XX[15] 0 89 - - -
29 AML-MDRC 47,XY,+8[20] 46,XY[15] 0 95 58 0 83
30 APL 47,XX,+8,t(15;17)(q22;q12)[15] /46,XX [5] 46,XX[15] 0 93 - 0 100
31 AML NOS 48,XY,+8,+8[18] 46,XY[15] 0 93.8 - 0 100
32 AML-MDRC 46,XY,-5,del(7)(q11q35),+8,der(17)t(5;17)
(p11;p11)[20]
No metaphases 0 84.8 - 0 100
Abbreviations: +8, trisomy 8; PB, peripheral blood; PHA, phytohemagglutinin; RA, refractory anemia; RCUD, refractory cytopenia with unilineage
dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, RA with excess of blasts; MDS-U, myelodysplastic syndrome unclassiﬁed;
RARS-T, RA with ringed sideroblasts and thrombocytosis; CMML, chronic myelomonocytic leukemia; AML, acute myeloid leukemia; AML-MDRC, AML
with myelodysplasia-related changes; AML NOS, AML not otherwise speciﬁed; APL, acute promyelocytic leukemia. In bold patient with constitutional
trisomy 8 mosaicism.
doi:10.1371/journal.pone.0129375.t001
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Outcome analysis
The data of twenty-one patients with MDS and +8 were available for Kaplan-Meier analysis.
Twelve patients died and five evolved to AML with a median follow up of 38.2 months (range,
2.6 to 92.3 months). The median OS and median time to AML transformation for MDS with
isolated +8 were 85.9 and 2.8 months, respectively. No statistically significant differences in
median OS were found between MDS with isolated +8 and MDS with +8 and another
additional aberration.
Discussion
MDS are associated with clonal cytogenetic abnormalities in around 50% of patients [2] being
trisomy 8 the most common chromosome gain. According to the IPSS-R, isolated trisomy 8 is
included in the intermediate cytogenetic risk group [4]. The current analysis with 22 patients
diagnosed of MDS with isolated +8 and selected to be alive at the inclusion moment showed a
longer overall survival (median, 85.9 months) than expected. However, in our previous study
of 72 MDS with isolated +8 patients from GESMDregistry, the median overall survival was
34.3 months [3], demonstrating the intermediate risk confered by trisomy 8 to MDS and in
agreement with IPSS-R. In contrast to other recurring chromosomal alterations, isolated +8 is
not considered presumptive evidence of MDS when minimal morphological criteria are lacking
[2]. This is in part because +8 may be derived from a constitutional 8 mosaicism. Furthermore,
the incidence of cT8M among general population is very low [6,7]. In accordance, none of our
healthy controls showed trisomy 8 by FISH. In 2002, Maserati et al. reported that +8 in myelo-
dysplasia and acute leukemia is constitutional in 15–20% [9]. They had analyzed 13 cases of
different myeloid neoplasms (including seven MDS) and 1 case of acute lymphoblastic leuke-
mia and reported a cT8M in two of them after applying conventional cytogenetics from PB
PHA-stimulated cultures. Nevertheless, in that study the cT8M was confirmed on a skin fibro-
blasts culture in only one MDS patient. Some other previous studies to determine lineage in-
volvement in MDS, demonstrated that +8 was only found in myeloid lineage (granulocytes,
monocytes and erythroblasts) [11–16]. These studies did not analyze non-hematopoietic cells
because of their different aim. We evaluated the presence of +8 in 32 patients with different
myeloid neoplasms (22 MDS, 2 RARS-T, 2 CMML and 6 AML). In all but one patient, we ob-
served the +8 in myeloid cells and ruled it out in CD3+ lymphocytes and mucosa cells by FISH.
Regarding the remaining patient, with +8 in both lymphocytes and mucosa cells, we could con-
sider this alteration as constitutional. We believe that G-banding cytogenetics from PB PHA-
stimulated cultures is not useful to discard cT8M, because myeloid cells present in these sam-
ples may also divide, giving a false positive result. In fact in our series, karyotype of PB showed
+8 in 3 MDS patients but none of them presented +8 in oral mucosa samples. Hence, we con-
sider it mandatory to apply FISH on isolated CD3+ lymphocytes as well as on non-hematologi-
cal cells as oral mucosa ones for mosaicism studies. In the present project, the study of mucosa
cells helps to rule out the germinal nature of trisomy 8 in those cases with residual positive
CD3+ cells from samples with low purity. Non-use of the FISH technique on non-hematologi-
cal cells probably explains the higher cT8M incidence reported fromMaserati analyses in a
short series with only 7 MDS patients [9]. Moreover, it is interesting to point out that the
CMML patient with constitutional +8 had been diagnosed with a Behçet syndrome. Curiously
the association between the presence of a cT8M and increased risk of developing Behçet syn-
drome [22] as well as a high risk of developing myeloid neoplasms [7,8,23], have already
been referred.
Another argument used against the value of +8 to diagnose MDS is the possible presence of
+8 as a seemingly clonal aberration in aplastic anemia (AA), which may disappear after
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immunosuppressive treatment [24]. Also Maciejewsky et al. have described a clonal evolution
to MDS as a late complication of AA [25]. Thus, +8 in the absence of unequivocal dysplasia,
would not be of help to differentiate hypocellular MDS from AA, entities that have been sug-
gested to share similar pathogenic process for bone marrow hypocellularity [26]. Furthermore,
a significant response rate of MDS with +8 to immunosuppressive therapy is well known [27].
In summary, our study confirms that cT8M should be ruled out using FISH on CD3+ lym-
phocytes and on non-hematological cells such as oral mucosa ones in MDS, and to the best of
our knowledge, is the first study performed under these conditions. Besides this, our results
suggest that trisomy 8 is acquired in almost all MDS, and probably, isolated +8 should be con-
sidered with enough evidence to diagnose MDS in normo and hypercellular bone marrow
cases. Studies with longer series are needed for more decisive conclusions.
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